Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 222.90 34.52% 57.20
ALNY closed up 34.52 percent on Monday, June 24, 2024, on 12.09 times normal volume. The bulls were able to push the stock to a new 52-week high.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 18 hours ago
2x Volume Pace about 18 hours ago
1.5x Volume Pace about 18 hours ago
3x Volume Pace about 18 hours ago
10x Volume Pace about 18 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Alnylam Pharmaceuticals, Inc. Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Cholesterol Liver Disease Amyloid Amyloidosis Huntington's Disease Hemoglobin Hemophilia Antitrypsin Deficiency Hypercholesterolemia Spinal Muscular Atrophy Genzyme Rna Interference Alnylam Pharmaceuticals Deficiency Hemophilia A Liver Cancer Thalassemia Therapeutic Gene Modulation Transthyretin Treatment Of Hemophilia Medtronic Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Beta Thalassemia Hemoglobinopathies Monsanto

Is ALNY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 231.64
52 Week Low 141.975
Average Volume 760,570
200-Day Moving Average 165.13
50-Day Moving Average 151.88
20-Day Moving Average 157.21
10-Day Moving Average 164.65
Average True Range 9.10
RSI (14) 87.92
ADX 22.67
+DI 66.44
-DI 7.64
Chandelier Exit (Long, 3 ATRs) 204.33
Chandelier Exit (Short, 3 ATRs) 174.10
Upper Bollinger Bands 188.89
Lower Bollinger Band 125.52
Percent B (%b) 1.54
BandWidth 40.31
MACD Line 7.85
MACD Signal Line 3.09
MACD Histogram 4.764
Fundamentals Value
Market Cap 27.97 Billion
Num Shares 125 Million
EPS -4.11
Price-to-Earnings (P/E) Ratio -54.23
Price-to-Sales 12.38
Price-to-Book 142.92
PEG Ratio -0.49
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 256.52
Resistance 3 (R3) 255.69 243.67 250.91
Resistance 2 (R2) 243.67 235.11 244.08 249.04
Resistance 1 (R1) 233.28 229.82 238.48 234.11 247.18
Pivot Point 221.26 221.26 223.85 221.67 221.26
Support 1 (S1) 210.87 212.70 216.07 211.70 198.62
Support 2 (S2) 198.85 207.41 199.26 196.76
Support 3 (S3) 188.46 198.85 194.89
Support 4 (S4) 189.29